Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Emad, Elkholy"'
Publikováno v:
In Current Problems in Cardiology June 2024 49(6)
Autor:
Khaled Elshammaa, Nouran Hamza, Emad Elkholy, Ahmad Mahrous, Mohamed Hassan Elnaem, Mahmoud E Elrggal
Publikováno v:
Saudi Pharmaceutical Journal, Vol 30, Iss 3, Pp 283-290 (2022)
Background: Pharmaceutical firms are striving to find potential treatments to prevent and treat COVID-19. One of the gold standards to evaluate treatment is a clinical trial; however, the difficulty in patient recruitment could act as a determinant.
Externí odkaz:
https://doaj.org/article/19dc1ac4c8e2471ba7746aad44891dc6
Autor:
Raghad Fodah, Moudhi Alkhalaf, Taif Alzahrani, Rahaf Halawani, Yosra Turkistani, Emad Elkholy, Yosra Alhindi, Sahar Elashmony, Arwa Fairaq
Publikováno v:
Medical Science. 27:1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaf6795352f0d46190d0d766b2bfb12a
https://doi.org/10.54905/disssi/v27i131/e2ms2640
https://doi.org/10.54905/disssi/v27i131/e2ms2640
Autor:
Emad Elkholy, Rafal Brashi, Raghad Batrafi, salma Alhadrami, Braah Almutawakkil, Hashim Atallah, Mohammed Mekkawy, Ghada Shalaby, mahmoud elragaal
Background: Factor X inhibition can cause the prolongation of PT by acting on the common pathway factors. Although, Expensive and less available “calibrated anti-FXa” predicts DOAC plasma level had better than prothrombin time (PT) and the intern
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34fdc212d3404fc7d4ece8816cc981f9
https://doi.org/10.21203/rs.3.rs-2687274/v1
https://doi.org/10.21203/rs.3.rs-2687274/v1
